Search Results Search Sort by RelevanceMost Recent Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care. Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852. Medicine and Society Nov 2019 What Are Good Guidelines for Evaluating Uterus Transplantation? Margaret Horvat, MA and Ana Iltis, PhD Recent advances in UTx suggest it is on a trajectory toward becoming an accepted clinical practice to treat absolute uterine factor infertility. AMA J Ethics. 2019;21(11):E988-995. doi: 10.1001/amajethics.2019.988. Medicine and Society Nov 2019 What Hand Transplantation Teaches Us About Embodiment Brock Bahler, PhD Current QoL conversations in HTx could be enhanced by a phenomenological account of temporality, embodiment, and intersubjectivity. AMA J Ethics. 2019;21(11):E996-1002. doi: 10.1001/amajethics.2019.996. Policy Forum Nov 2019 Why Quality-of-Life Data Collection and Use Should Be Standardized When Evaluating Candidates for Hand Transplantation Martin Kumnig, PhD, MSc, Emma K. Massey, PhD, and Lisa S. Parker, PhD Improving candidate evaluation and informed consent is key to motivating authenticity, not just voluntariness. AMA J Ethics. 2019;21(11):E974-979. doi: 10.1001/amajethics.2019.974. State of the Art and Science Feb 2017 Reasonableness, Credibility, and Clinical Disagreement Mary Jean Walker, PhD and Wendy A. Rogers, BMBS, PhD When is a source credible and how do beliefs about a source’s credibility influence assessments of evidence? AMA J Ethics. 2017;19(2):176-182. doi: 10.1001/journalofethics.2017.19.2.stas1-1702. Policy Forum Feb 2017 What Is the Relevance of Procedural Fairness to Making Determinations about Medical Evidence? Govind Persad, JD, PhD Procedures for weighing factual evidence could help avoid the epistemic injustice of discounting or ignoring the voices of clinical research subjects. AMA J Ethics. 2017;19(2):183-191. doi: 10.1001/journalofethics.2017.19.2.pfor1-1702. Policy Forum Feb 2017 Seeking Legitimacy for DSM-5: The Bereavement Exception as an Example of Failed Process James E. Sabin, MD and Norman Daniels, PhD The DSM-5 Task Force’s handling of the ethical controversy over the bereavement exclusion demonstrates the need for more inclusive deliberative processes. AMA J Ethics. 2017;19(2):192-198. doi: 10.1001/journalofethics.2017.19.2.pfor2-1702. Medicine and Society Feb 2017 The Case of Dr. Oz: Ethics, Evidence, and Does Professional Self-Regulation Work? Jon C. Tilburt, MD, MPH, Megan Allyse, PhD, and Frederic W. Hafferty, PhD Dr. Oz’s advice has raised ethical questions about medicine as a profession, its evidentiary standards, and its role in maintaining public trust. AMA J Ethics. 2017;19(2):199-206. doi: 10.1001/journalofethics.2017.19.2.msoc1-1702. Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575. Pagination First page « First Previous page ‹ Previous Page 1 Page 2 Current page 3 Page 4 Page 5 Page 6 Page 7 Page 8 Page 9 … Next page Next › Last page Last »
Podcast May 2019 Ethics Talk: When and How Should ECMO Be Initiated and Removed? When should ECMO be started and stopped? This month’s Ethics Talk explores ethical challenges of ECMO use in end-of-life care.
Case and Commentary Oct 2019 How Should Decision Science Inform Scarce Blood Product Allocation? Eric Kersjes, MD and Lauren B. Smith, MD Decision aids could help clinicians know when to request ethics consultation or re-evaluate blood product usage in a specific patient care situation. AMA J Ethics. 2019;21(10):E852-857. doi: 10.1001/amajethics.2019.852.
Medicine and Society Nov 2019 What Are Good Guidelines for Evaluating Uterus Transplantation? Margaret Horvat, MA and Ana Iltis, PhD Recent advances in UTx suggest it is on a trajectory toward becoming an accepted clinical practice to treat absolute uterine factor infertility. AMA J Ethics. 2019;21(11):E988-995. doi: 10.1001/amajethics.2019.988.
Medicine and Society Nov 2019 What Hand Transplantation Teaches Us About Embodiment Brock Bahler, PhD Current QoL conversations in HTx could be enhanced by a phenomenological account of temporality, embodiment, and intersubjectivity. AMA J Ethics. 2019;21(11):E996-1002. doi: 10.1001/amajethics.2019.996.
Policy Forum Nov 2019 Why Quality-of-Life Data Collection and Use Should Be Standardized When Evaluating Candidates for Hand Transplantation Martin Kumnig, PhD, MSc, Emma K. Massey, PhD, and Lisa S. Parker, PhD Improving candidate evaluation and informed consent is key to motivating authenticity, not just voluntariness. AMA J Ethics. 2019;21(11):E974-979. doi: 10.1001/amajethics.2019.974.
State of the Art and Science Feb 2017 Reasonableness, Credibility, and Clinical Disagreement Mary Jean Walker, PhD and Wendy A. Rogers, BMBS, PhD When is a source credible and how do beliefs about a source’s credibility influence assessments of evidence? AMA J Ethics. 2017;19(2):176-182. doi: 10.1001/journalofethics.2017.19.2.stas1-1702.
Policy Forum Feb 2017 What Is the Relevance of Procedural Fairness to Making Determinations about Medical Evidence? Govind Persad, JD, PhD Procedures for weighing factual evidence could help avoid the epistemic injustice of discounting or ignoring the voices of clinical research subjects. AMA J Ethics. 2017;19(2):183-191. doi: 10.1001/journalofethics.2017.19.2.pfor1-1702.
Policy Forum Feb 2017 Seeking Legitimacy for DSM-5: The Bereavement Exception as an Example of Failed Process James E. Sabin, MD and Norman Daniels, PhD The DSM-5 Task Force’s handling of the ethical controversy over the bereavement exclusion demonstrates the need for more inclusive deliberative processes. AMA J Ethics. 2017;19(2):192-198. doi: 10.1001/journalofethics.2017.19.2.pfor2-1702.
Medicine and Society Feb 2017 The Case of Dr. Oz: Ethics, Evidence, and Does Professional Self-Regulation Work? Jon C. Tilburt, MD, MPH, Megan Allyse, PhD, and Frederic W. Hafferty, PhD Dr. Oz’s advice has raised ethical questions about medicine as a profession, its evidentiary standards, and its role in maintaining public trust. AMA J Ethics. 2017;19(2):199-206. doi: 10.1001/journalofethics.2017.19.2.msoc1-1702.
Case and Commentary Jul 2019 Should Dialysis Be Stopped for an Unrepresented Patient With Metastatic Cancer? Adira Hulkower, JD, MS, Sarah Garijo-Garde, and Lauren S. Flicker, JD, MBE Legal inconsistencies and variation in end-of-life options generate disparities in care for unrepresented patients. AMA J Ethics. 2019;21(7):E575-581. doi: 10.1001/amajethics.2019.575.